Results 61 to 70 of about 3,746,725 (298)

Influence of drug–drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus [PDF]

, 2019
[Abstract] Objectives Direct-acting antivirals are the recommended treatment for hepatitis C-infected patients. Drug–drug interactions with concomitant treatments can cause lack of effectiveness and/or safety.
Martín-Herranz, Isabel, Mena, Álvaro, Margusino-Framiñán, Luis, Mondelo-García, Cristina, Fernández-Oliveira, Carla, Cid-Silva, Purificación, Castro-Iglesias, Ángeles, Giménez-Arufe, Víctor   +7 more
core   +1 more source

Direct-Acting Antiviral Agents and the Path to Interferon Independence [PDF]

Clinical Gastroenterology and Hepatology, 2014
Chronic infection with hepatitis C virus (HCV) is a major global health problem; there are approximately 120 to 130 million chronic infections worldwide. Since the discovery of HCV 24 years ago, there has been a relentless effort to develop successful antiviral therapies.
Warren N, Schmidt, David R, Nelson, Jean-Michel, Pawlotsky, Kenneth E, Sherman, David L, Thomas, Raymond T, Chung   +5 more
openaire   +2 more sources

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study [PDF]

, 2018
In the Swiss HIV Cohort Study, the number of people who inject drugs with replicating hepatitis C virus (HCV) infection decreased substantially after the introduction of direct-acting antivirals (DAAs).
Swiss HIV Cohort Study, Fehr, Jan, Hoffmann, Matthias, Salazar-Vizcaya, Luisa, Rauch, Andri, Wandeler, Gilles, Rougemont, Mathieu, Béguelin, Charles, Braun, Dominique, Béguelin, Charles; https://orcid.org/, Stoeckle, Marcel, Cavassini, Matthias, Bernasconi, Enos, Rougemont, M., Béguelin C, Cavassini, M., Wandeler, G., Wandeler G, Braun, D., Rauch, A., Cavassini M, Braun D, Fehr J, Stoeckle, M., Rauch A, Stoeckle M, Hoffmann, M., Béguelin, C., Rougemont M, Salazar-Vizcaya L, Salazar-Vizcaya, L., Hoffmann M, Fehr, J., Bernasconi E, Bernasconi, E.   +34 more
core   +2 more sources

Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'LIver Network Activity' (LINA) cohort update results

, 2021
Second generation direct acting antivirals (DAAs) drastically changed the landscape of chronic HCV (CHCV). Aim of this paper was to assess the effectiveness of DAAs, also looking at the demographic characteristics of subjects ...
Mercinelli, Simona, Pinchera, Biagio, Stanzione, Maria, Buonomo, Antonio Riccardo, Coppola, Nicola, Staiano, Laura, Nerilli, Mariagiovanna, Coppola, Carmine, Stornaiuolo, Gianfranca, Scotto, Riccardo, Gentile, Ivan, Messina, Vincenzo, Cattaneo, Letizia, De Pascalis, Stefania, Martini, Salvatore   +14 more
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Aggressive recurrence of Non-Hodgkin's Lymphoma after successful clearance of hepatitis C virus with direct acting antivirals

, 2021
The association of Non-Hodgkin lymphomas and Hepatitis C virus is well documented and antiviral treatments facilitate a virological and hematological response in the majority of HCV related Non-Hodgkin lymphomas.
Konstantia I. Pavlaki, Maria Tzardi, Elias Kehagias, Maria Psyllaki, Elias Drakos, Helen A. Papadaki, Dimitrios N. Samonakis   +6 more
core   +1 more source

APOBEC3 activity and DNA polymerase‐ε deficiency are associated with distinct IDH1 R132 hotspot mutations

Molecular Oncology, EarlyView.
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler, Bilal A. Lone, Ecem Unal, A. Rouf Banday   +3 more
wiley   +1 more source

Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals [PDF]

, 2019
BACKGROUND: Direct-acting antivirals (DAAs) are effective in patients aged >/=65 years. However, little is known about the effects of DAAs on survival, liver decompensation and development of hepatocellular carcinoma (HCC).
Morano Amado, Luis, Rodríguez Osorio, Iria, Margusino Framiñán, Luis, Cid Silva, Purificación, Pedreira Andrade, José Domingo, Castro Iglesias, Angeles, Mena de Cea, Alvaro, Delgado Blanco, Manuel, Meijide Miguez, Hector M   +8 more
core   +1 more source